Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Silymarin137 records.
Article ID | PMID | Source | Title | Publish Year | |
---|---|---|---|---|---|
A42432 | 34540892 | Front Mol Biosci | Therapeutic Effects of an Inhibitor of Thioredoxin Reductase on Liver Fibrosis by Inhibiting the Transforming Growth Factor-β1/Smads Pathway. | 2021 | Details |
A42627 | 33980244 | BMC Complement Med Ther | Correction to: Hepatoprotective effect of silymarin on fructose induced nonalcoholic fatty liver disease in male albino wistar rats. | 2021 | Details |
A44032 | 30080294 | Phytother Res | Milk thistle (Silybum marianum): A concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases. | 2018 | Details |
A44370 | 28804034 | Clin Gastroenterol Hepatol | Silymarin for Treatment of Nonalcoholic Steatohepatitis-A New Kid on the Block? | 2017 | Details |
A44964 | 26592819 | Eur Rev Med Pharmacol Sci | Reply to the Letter "Effect of anti-oxidant agents in patients with hepatocellular diseases". | 2015 | Details |
A44965 | 26592818 | Eur Rev Med Pharmacol Sci | Effect of anti-oxidant agents in patients with hepatocellular diseases. | 2015 | Details |
A45187 | 25767868 | MMW Fortschr Med | [Interview with PD Dr. Anton Gillessen, Münster. Non-alcoholic fatty liver: change in the life style!]. | 2015 | Details |
A45436 | 24597776 | J Nat Prod | Identification of isosilybin a from milk thistle seeds as an agonist of peroxisome proliferator-activated receptor gamma. | 2014 | Details |
A45525 | 24134155 | Expert Rev Gastroenterol Hepatol | Milk thistle to treat non-alcoholic fatty liver disease: dream or reality? | 2013 | Details |
A45702 | 23213025 | Hepatology | Hepatoprotective and antiviral functions of silymarin components in hepatitis C virus infection. | 2013 | Details |
A45822 | 22527892 | Endocrine | Anti-oxidant therapy in non-alcoholic fatty liver disease: the role of silymarin. | 2012 | Details |
A45997 | 21696523 | Hepatol Res | Role of silymarin to treat fibrosis development in non-alcoholic fatty liver disease. | 2011 | Details |
A46252 | 20008062 | J Pharmacol Exp Ther | A silybin-phospholipid complex prevents mitochondrial dysfunction in a rodent model of nonalcoholic steatohepatitis. | 2009 | Details |
A46447 | 18566043 | Drug Metab Dispos | The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic Fatty liver disease and correlates with plasma caspase-3/7 activity. | 2008 | Details |
A46590 | 17410454 | Dig Dis Sci | The effect of a silybin-vitamin e-phospholipid complex on nonalcoholic fatty liver disease: a pilot study. | 2007 | Details |
A46674 | 16698763 | Gut | A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: preliminary observations. | 2006 | Details |
A46818 | 14720455 | Curr Gastroenterol Rep | New concepts of the pathogenesis of alcoholic liver disease lead to novel treatments. | 2004 | Details |
A47018 | 29708448 | Expert Opin Pharmacother | Alcoholic steatohepatitis (ASH) and alcoholic hepatitis (AH): cascade of events, clinical aspects, and pharmacotherapy options. | 2018 | Details |
A47251 | 21401100 | J Agric Food Chem | Effects of Antrodia camphorata on alcohol clearance and antifibrosis in livers of rats continuously fed alcohol. | 2011 | Details |
A47255 | 21105651 | J Agric Food Chem | Gentiana manshurica Kitagawa reverses acute alcohol-induced liver steatosis through blocking sterol regulatory element-binding protein-1 maturation. | 2010 | Details |
A47262 | 20192205 | J Agric Food Chem | Fruiting body of Niuchangchih (Antrodia camphorata) protects livers against chronic alcohol consumption damage. | 2010 | Details |
A47314 | 17453353 | Cell Biol Toxicol | Fenugreek seed (Trigonella foenum graecum) polyphenols inhibit ethanol-induced collagen and lipid accumulation in rat liver. | 2007 | Details |
A47357 | 12860315 | J Ethnopharmacol | Antihepatotoxic activity of seeds of Cichorium intybus. | 2003 | Details |
A47465 | 1345200 | Acta Physiol Hung | Pathogenesis and management of alcoholic liver injury. | 1992 | Details |
A49009 | 21466434 | Curr Pharm Biotechnol | Silymarin in the prevention and treatment of liver diseases and primary liver cancer. | 2012 | Details |
A49099 | 17845508 | Basic Clin Pharmacol Toxicol | Silymarin prevents palmitate-induced lipotoxicity in HepG2 cells: involvement of maintenance of Akt kinase activation. | 2007 | Details |
A49144 | 16296871 | Drugs | Pathophysiological basis for antioxidant therapy in chronic liver disease. | 2005 | Details |
A49653 | 35678658 | Curr Issues Mol Biol | Beneficial Effect of Fenofibrate and Silymarin on Hepatic Steatosis and Gene Expression of Lipogenic and Cytochrome P450 Enzymes in Non-Obese Hereditary Hypertriglyceridemic Rats. | 2022 | Details |
A49744 | 35651885 | Metabol Open | Effect of 8 Weeks milk thistle powder (silymarin extract) supplementation on fatty liver disease in patients candidates for bariatric surgery. | 2022 | Details |
A49797 | 35635048 | Ann Med | Role of silymarin as antioxidant in clinical management of chronic liver diseases: a narrative review. | 2022 | Details |
A49905 | 35602098 | Oxid Med Cell Longev | A Molecular Insight into the Role of Antioxidants in Nonalcoholic Fatty Liver Diseases. | 2022 | Details |
A49958 | 35582982 | Obes Rev | The effect of pharmacological treatment and lifestyle modification in patients with nonalcoholic fatty liver disease: An umbrella review of meta-analyses of randomized controlled trials. | 2022 | Details |
A50776 | 35269912 | Int J Mol Sci | Natural Compounds for Counteracting Nonalcoholic Fatty Liver Disease (NAFLD): Advantages and Limitations of the Suggested Candidates. | 2022 | Details |
A51132 | 35577653 | Nutrition | May Silymarin be selectively considered for nonalcoholic fatty liver disease without elevated transaminases? Comment re. "Impact of Silymarin in individuals with nonalcoholic fatty liver disease: a systematic review and meta-analysis". | 2022 | Details |
A51474 | 31600349 | PLoS One | Correction: Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial. | 2019 | Details |
A51889 | 33447529 | J Clin Transl Hepatol | Chronic Liver Disease and Silymarin: A Biochemical and Clinical Review. | 2020 | Details |
A52631 | 24486395 | Eur J Pharmacol | Silymarin ameliorates fructose induced insulin resistance syndrome by reducing de novo hepatic lipogenesis in the rat. | 2014 | Details |